Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 15 April 2013 | By Louise Zornoza
The board of Brazil's National Health Surveillance Agency (Anvisa) has approved updated rules for the agency's prior consent assessment of patent applications for medicines.
The new rules establish a process for prioritizing patent reviews to ensure that the focus is on pharmaceutical products of interest to the public health policies of the country's Unified Health System (SUS).
The list of products of interest to the SUS will be published by the Ministry of Health, which will also require Anvisa to deny patent applications dealing with products prohibited in Brazil. According to Anvisa's director, Dirceu Barbano, the main advance in the updated rules is to define what is in the public interest and to allow the Agency to take a more strategic approach to products.
Tags: Latest News, Patent, pharmaceutical, brazil, drug